The goal of this clinical trial is to compare an optimized dose (1800 mg) of rifampicin to
standard dose (450 mg if patient <50 kg and 600 mg if patient >50kg) of rifampicin in
tuberculosis patients.
The main questions it aims to answer are:
- To compare the incidence of hepatotoxicity occurs in the optimized dose vs standard dose
arm
- To compare any adverse events occur in the optimized dose vs standard dose arm
- To compare final treatment outcome at the end of treatment according to WHO definitions
of cure in the optimized dose regimen versus the standard dose regimen.
- To compare two and three months culture conversion rates in the optimized dose regimen
versus the standard dose regimen.
- To describe and compare the steady-state plasma pharmacokinetics of the optimized dose
regimen versus the standard dose regimen.
Participants will be given an optimized dose of 1800 mg of rifampicin daily. Researchers will
compare the optimized and standard dose to see if more hepatotoxicity occurs.